[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363429-105":59,"doc-detail-363429-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","prognostic-and-therapeutic-significance-of-dpp4-in-smarca4-deficient-nonsmall-cell-lung-cancer","Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer","","SMARCA4-deficient non–small cell lung cancer (SMARCA4-dNSCLC) is an aggressive subtype without robust biomarkers or targets. The study evaluates DPP4 expression patterns and clinical relevance, analyzing TCGA cohorts and an immunohistochemistry case series. DPP4 is downregulated in SMARCA4-low tumors versus adjacent normal lung, yet higher residual DPP4 associates with poorer overall and disease-free survival. In vitro, SMARCA4 knockdown and DPP4 inhibition reduce clonogenic growth and motility, with the combined treatment showing the strongest effects.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-and-therapeutic-significance-of-dpp4-in-smarca4-deficient-nonsmall-cell-lung-cancer/363429/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-and-therapeutic-significance-of-dpp4-in-smarca4-deficient-nonsmall-cell-lung-cancer/363429.png","ImageObject",300,407,{"name":92,"@type":93},"Grenda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main research question about DPP4 in SMARCA4-deficient NSCLC?","Question",{"text":112,"@type":113},"The study asks whether DPP4 expression and clinical associations can indicate prognostic value and reveal therapeutic vulnerability in SMARCA4-dNSCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DPP4 expression measured and defined in the clinical case series?",{"text":117,"@type":113},"DPP4 was quantified by immunohistochemistry as the percentage of tumor cells. A cutoff of ≥20% tumor cells defined DPP4-high status.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship did the study find between DPP4 levels and patient survival?",{"text":121,"@type":113},"Although DPP4 was lower in SMARCA4-low tumors than adjacent normal lung, higher residual DPP4 within tumors correlated with worse overall and disease-free survival.",{"name":123,"@type":110,"acceptedAnswer":124},"How did SMARCA4 knockdown and DPP4 inhibition affect cancer cell behavior in vitro?",{"text":125,"@type":113},"Both SMARCA4 knockdown and DPP4 inhibition reduced clonogenic growth and motility. The combined approach produced the greatest inhibition compared with either treatment alone.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},363429,1790550082,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer  \nTechnology in Cancer Research & Treatment Volume 25: 1–18 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/15330338261452636](DOI: 10.1177/15330338261452636)  \n[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nChaopeng Chen1, Zebin Zhong2, Xiaoling Luo2, Weiping Dai1, Lujian Xu3, Wenping Cai4, Zhibin Xu5 , Guolian Liang6, and Lijuan Pang7  \nAbstract  \nIntroduction: SMARCA4-deficient NSCLC is an aggressive subtype lacking robust biomarkers and therapeutic targets. To define the expression pattern and clinical significance of DPP4 in SMARCA4-dNSCLC and explore whether DPP4 may represent a therapeutic vulnerability in this subtype. Materials and Methods: The Cancer Genome Atlas NSCLC cohort was analyzed to compareSMARCA4-low tumors with adjacent normal lung using differential expression, Cox regression, protein– protein interaction networks, and machine-learning ranking. An exploratory immunohistochemistry case series ofSMARCA4-dNSCLC from three centers (n=9) quantified DPP4 by percentage of tumor cells; ≥20% cells defined DPP4-high. Clinicopathologic features, RECIST response, and survival were summarized descriptively by DPP4 status. In HCC827 cells, SMARCA4 knockdown and DPP4 inhibition (P32/98) were evaluated alone and in combination using colony-formation, and motility (migration/wound-healing) assays. Results: DPP4 was downregulated in SMARCA4-low tumors versus adjacent normal lung, yet within tumors higher residual DPP4 expression was associated with worse overall and disease-free survival. In the immunohistochemistry case series, DPP4 protein expression was weaker in SMARCA4-dNSCLC than in adjacent alveolar epithelium. Within this low-expressing background, DPP4-high tumors showed descriptive trends toward inferior survival, lower disease-control rate after first-line therapy, and more extensive baseline organ involvement than DPP4-low tumors. In vitro, SMARCA4 knockdown and P32/98 each reduced clonogenic growth and motility versus control, with the combination producing the greatest inhibition (about 60%–70% reductions) . Conclusions: DPP4 is downregulated at themRNA and protein levels in SMARCA4-dNSCLC compared with normal lung, yet higher residual expression may mark a more aggressive phenotype. Combined SMARCA4 knockdown and DPP4 inhibition suppress growth and motility in vitro, suggesting DPP4 as a candidate prognostic marker and a candidate therapeutic target that requires orthogonal specificity controls and validation in larger cohorts.  \n1Department of Pathology, Guangdong Nongken Central School of Clinical Medicine, Guangdong Medical University (Central Hospital of Guangdong Provincial Nongken), Zhanjiang, Guangdong, China  \n2Department of Pathology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China  \n3Department of Imaging, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China  \n4Department of Pathology, Guangdong Medical University (Central People’s Hospital of Zhanjiang), Zhanjiang, Guangdong, China  \n5Department of Organ Transplantation, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China  \n6Department of Thoracic Surgery, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China  \n7Zhanjiang Central School of Clinical Medicine, Guangdong Medical University (Central People’s Hospital of Zhanjiang), Zhanjiang, Guangdong, China  \nCorresponding author:  \nLijuan Pang, Zhanjiang Central School of Clinical Medicine, Guangdong Medical University (Central People’s Hospital of Zhanjiang), Zhanjiang, Guangdong, China.  \nEma","cbCaidxfYta8JUmW","https://ap.wps.com/l/cbCaidxfYta8JUmW","pdf",3408936,18,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What is the main research question about DPP4 in SMARCA4-deficient NSCLC?\",\"answer\":\"The study asks whether DPP4 expression and clinical associations can indicate prognostic value and reveal therapeutic vulnerability in SMARCA4-dNSCLC.\"},{\"question\":\"How was DPP4 expression measured and defined in the clinical case series?\",\"answer\":\"DPP4 was quantified by immunohistochemistry as the percentage of tumor cells. A cutoff of ≥20% tumor cells defined DPP4-high status.\"},{\"question\":\"What relationship did the study find between DPP4 levels and patient survival?\",\"answer\":\"Although DPP4 was lower in SMARCA4-low tumors than adjacent normal lung, higher residual DPP4 within tumors correlated with worse overall and disease-free survival.\"},{\"question\":\"How did SMARCA4 knockdown and DPP4 inhibition affect cancer cell behavior in vitro?\",\"answer\":\"Both SMARCA4 knockdown and DPP4 inhibition reduced clonogenic growth and motility. The combined approach produced the greatest inhibition compared with either treatment alone.\"}]","Prognostic and Therapeutic Significance of DPP4 in SMARCA4-Deficient Non–Small Cell Lung Cancer | PDF",1790151207,45,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf0b4b721472d71cb3fdef1727913496.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/527d85b3826e883b54c77a0d38830e61.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41409b8bd4041f678d68dbded9f348e2.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d46a123c712d59d2152eaa9d5ba884e.webp",980,1306]